Rekanalizácia pazeráka pri pokrocilom ezofageálnom karcinóme
[Advanced esophageal carcinoma recanalization]
Jazyk slovenština Země Česko Médium print
Typ dokumentu anglický abstrakt, časopisecké články, přehledy
PubMed
19202963
- MeSH
- brachyterapie MeSH
- katetrizace MeSH
- lidé MeSH
- nádory jícnu komplikace patologie terapie MeSH
- paliativní péče * MeSH
- poruchy polykání etiologie terapie MeSH
- stenty MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- přehledy MeSH
Advanced esophageal carcinoma has poor prognosis with 5-year survival of less than 20%. This poor prognosis is the same for squamous cell carcinoma and adenocarcinoma. Surgical therapy, external radiation and chemotherapy with curative intent are usually impossible because of the advanced disease. Dysphagia is the most frequent symptom affecting quality of life. Bougies or balloon dilation improves dysphagia only short-term (few days). Nd-YAG laser, ACP and photodynamic therapy all have mid-range effect and require repetition after few weeks. Brachytherapy and esophageal self-expanding stent insertion have longer benefit. Stent insertion provides fastest improvement of dysphagia; however, complications in later setting occur in30% and require further endoscopic treatment. Brachytherapy has slower onset of benefit but has fewer complications and longer benefit. Brachytherapy is suitable for patients wit expected lifespan more than 3 months. Most important contraindication of brachytherapy is tracheo-esophageal fistula.